-
Managing Neonatal Abstinence Syndrome: Screening and Medication Monitoring
Neonatal abstinence syndrome (NAS) affects infants who were exposed to opioids or other substances while in the womb.1 NAS has become more common in recent…
-
Novel Psychoactive Substances: Newly Identified Threats Detected in the Second Half of 2022
Novel Psychoactive Substances (NPS) are a diverse group of synthetic substances created to mimic the effects of scheduled or illicit drugs. There are various…
-
Impacts of Bariatric Surgery
Bariatric Surgeries1,2,6 Restrictive procedures Sleeve gastrectomy Gastric banding Vertical banded gastroplasty Malabsorptive procedures –…
-
Novel Psychoactive Substances: What is Xylazine?
Substance use can take many forms and often involves many unknowns. One of the most important aspects of illicit substance use, especially for the end…
-
Medication Monitoring in a Changing Opioid Prescribing Landscape
The new 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain is an update to the most recent practice guideline published in 2016.1,2…
-
Aegis's Novel Psychoactive Substance (NPS) Testing Menu Update
In September, Aegis updated both urine and oral fluid novel psychoactive substance (NPS) test menus as a continued commitment to offering providers a contemporary…
-
InterACT Rx Pharmacodynamic Insights: A Brief Look at QTc Prolongation, Serotonin Syndrome, and Tardive Dyskinesia
Introduction Some combinations of medications can lead to serious pharmacodynamic interactions with clinical effects that can be life-threatening in some…